(WVE) Wave Life Sciences - Ratings and Ratios
Exchange: NASDAQ • Country: Singapore • Currency: USD • Type: Common Stock • ISIN: SG9999014716
WVE: RNA, Medicines, Oligonucleotides, Therapeutics
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that specializes in the design, development, and commercialization of innovative RNA medicines. At the core of their approach is PRISM, a proprietary discovery and drug development platform that integrates multiple RNA modalities, cutting-edge chemistry, and deep insights into human genetics. This platform is designed to address a wide range of rare and prevalent disorders by delivering precise and targeted therapeutic solutions.
The companys pipeline is diverse, focusing on several high-impact therapeutic areas. WVE-006 is an RNA editing oligonucleotide currently in development for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can lead to severe lung and liver disease. Additionally, Wave is advancing an siRNA clinical candidate for obesity and other metabolic disorders, targeting a condition that affects millions globally. WVE-N531, an exon-skipping oligonucleotide, is being developed for Duchenne muscular dystrophy, a devastating genetic disorder affecting muscle function. Furthermore, WVE-003, an antisense silencing oligonucleotide, is in development for Huntingtons disease, a progressive neurodegenerative disorder with significant unmet medical need.
Wave has established strategic collaborations to enhance its research and development capabilities. Notably, the company has partnered with GlaxoSmithKline (GSK) to co-develop and commercialize oligonucleotide therapeutics, leveraging GSKs extensive expertise in drug development and commercialization. Another key partnership is with Takeda Pharmaceutical Company Limited, focusing on CNS disorders, an area where RNA-based therapies hold great promise. Additionally, Wave has collaborated with Asuragen, Inc. to develop companion diagnostics for its allele-selective therapeutic programs targeting Huntingtons disease, ensuring that patients can benefit from personalized treatment approaches.
Founded in 2012 and headquartered in Singapore, Wave Life Sciences has rapidly emerged as a leader in the RNA therapeutics space. The companys market capitalization stands at approximately $1.7 billion, reflecting investor confidence in its innovative platform and pipeline. While the company is currently pre-revenue, its focus on advancing a versatile RNA platform positions it as a high-risk, high-reward opportunity in the biotechnology sector. Investors should closely monitor the progress of its clinical programs and collaborations, as success in any of these areas could significantly impact the companys valuation.
For more information, visit their website at https://www.wavelifesciences.com.
Additional Sources for WVE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
WVE Stock Overview
Market Cap in USD | 1,443m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2015-11-11 |
WVE Stock Ratings
Growth 5y | 18.4% |
Fundamental | -35.6% |
Dividend | 0.0% |
Rel. Strength Industry | 57.8 |
Analysts | 4.6/5 |
Fair Price Momentum | 9.24 USD |
Fair Price DCF | - |
WVE Dividends
No Dividends PaidWVE Growth Ratios
Growth Correlation 3m | -90.2% |
Growth Correlation 12m | 70.8% |
Growth Correlation 5y | -12.5% |
CAGR 5y | 4.88% |
CAGR/Max DD 5y | 0.05 |
Sharpe Ratio 12m | -0.15 |
Alpha | 38.83 |
Beta | 2.49 |
Volatility | 91.48% |
Current Volume | 743.4k |
Average Volume 20d | 1082.2k |
As of March 15, 2025, the stock is trading at USD 10.22 with a total of 743,384 shares traded.
Over the past week, the price has changed by +8.72%, over one month by -5.46%, over three months by -24.01% and over the past year by +59.19%.
Probably not. Based on ValueRay Fundamental Analyses, Wave Life Sciences (NASDAQ:WVE) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.63 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of WVE as of March 2025 is 9.24. This means that WVE is currently overvalued and has a potential downside of -9.59%.
Wave Life Sciences has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy WVE.
- Strong Buy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, WVE Wave Life Sciences will be worth about 10.9 in March 2026. The stock is currently trading at 10.22. This means that the stock has a potential upside of +6.65%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.9 | 124.2% |
Analysts Target Price | 22.3 | 118.2% |
ValueRay Target Price | 10.9 | 6.7% |